source
- Compliance worries keep AI adoption in drug manufacturing low, survey findsA new survey of more than 400 research and manufacturing professionals shows that over 90% of drugmakers have not committed to expanding AI use in regulated drug production. While AI is widely em…
- Experts warn FDA against approving Grail’s ineffective multicancer blood testPhysician and cancer‑screening researcher H. Gilbert Welch argues that the FDA should not greenlight Grail’s multicancer blood test, noting the company’s trial of 140,000 participants used a weak s…